COMMUNIQUÉS West-GlobeNewswire

Pharvaris Announces Extraordinary Meeting of Shareholders
16/02/2024
ZUG, Switzerland , Feb. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks [...]
Vistin Pharma ASA: Key information relating to the proposed cash dividend
16/02/2024
The Board of Directors of Vistin Pharma ASA plans to propose to distribute a cash dividend of total NOK 1.00 per share, to be paid partly in June and November, for the accounting year of 2023. The formal decision [...]
Smart Immune appoints key new members to its Board of Directors
16/02/2024
Smart Immune appoints key new members to its Board of Directors PARIS, France, 16 February 2024 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T cell progenitor therapy [...]
Vistin Pharma ASA: Fourth quarter and preliminary 2023 financial results
16/02/2024
Oslo, Norway, 16 th of February 2024 Vistin Pharma ASA (Vistin Pharma, OSE: VISTN) today announces the financial results for the fourth quarter of 2023. Vistin delivers another strong quarter with a 12% revenue growth [...]
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
16/02/2024
Japan first in the world to approve Dupixent ® for chronic spontaneous urticaria (CSU) Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the [...]
Communiqué de presse : Le Japon est le premier pays dans le monde à approuver Dupixent® pour le traitement de l’urticaire chronique spontanée
16/02/2024
Le Japon est le premier pays dans le monde à approuver Dupixent ® pour le traitement de l’urticaire chronique spontanée L’approbation est fondée essentiellement sur les résultats d’un essai de phase III ayant montré que [...]
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
16/02/2024
Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dupixent globally [...]
Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office
16/02/2024
Tokyo, Japan and Cambridge, UK, 16 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), today announces that at a meeting held on 15 February 2024, its Board of Directors resolved to [...]
Sirona Biochem Provides Update on Loan
15/02/2024
VANCOUVER, British Columbia, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“ Sirona ” or the “ Company ”) announce that, further to its news release on January 29, 2024, [...]
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
15/02/2024
EDMONTON, Alberta, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“ Ceapro ” or the “ Company ”) is pleased to announce that it has mailed and filed a management information circular dated [...]
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
15/02/2024
Aeterna Zentaris Board recommends shareholders vote FOR all resolutions, to create a diversified biopharmaceutical company with a compelling value proposition More information and materials available at www.AEZSmerger. [...]
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
15/02/2024
Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at € 0.01 million 2 , and long-term deposit at €9.0 million 3 as of [...]
Inventiva publie ses informations financières préliminaires pour l’exercice fiscal 2023¹ et fait le point sur son étude clinique NATiV3
15/02/2024
Chiffre d’affaires de 17,5 millions d’euros pour l’année 2023, contre 12,2 millions d’euros sur la même période en 2022 Trésorerie et équivalents de trésorerie à 26,9 millions d’euros, dépôt à court-terme de 0,01 [...]
BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2023 Financial Results and Hold Investor Conference Call on February 29, 2024
15/02/2024
LOUISVILLE, Ky., Feb. 15, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its fourth quarter and full year 2023 [...]
Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024
15/02/2024
Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024 Mont-Saint-Guibert, Belgium – February 15, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah [...]
Nyxoah Publiera ses Résultats Financiers du Quatrième Trimestre et de l'Exercice 2023 le 5 Mars 2024
15/02/2024
Nyxoah Publiera ses Résultats Financiers du Quatrième Trimestre et de l'Exercice 2023 le 5 Mars 2024 Mont-Saint-Guibert, Belgique – 15 février 2024, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH [...]
Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow
15/02/2024
TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update
15/02/2024
Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement Until March 25, 2024 Net Revenue for Full Year 2023 Expected to be in the Range of $20 [...]
CooperCompanies 4-for-1 Stock Split Effective Friday (2/16)
15/02/2024
SAN RAMON, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced that its four-for-one stock split will become effective on Friday, February 16, 2024, at 5:00 PM ET, and trading is [...]

Pages